Dyax Launches Confirmatory DX-88 Study Requested By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Late 2008 approval for the experimental hereditary angioedema treatment is anticipated.
You may also be interested in...
Jerini’s Icatibant Falters in U.S., Wins In Europe
FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.
Jerini’s Icatibant Falters in U.S., Wins In Europe
FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.
Dyax/Bayer Schering Ink Antibody Discovery Agreement
External licensing and discovery agreements support internal pipeline growth, goal of total integration, Dyax CEO tells “The Pink Sheet” DAILY.